TABLE 3.
Hemodynamic measurements post-TAC in the β-cateninfl/fl/Cre mice and β-cateninfl/fl/WT mice, treated with tamoxifen (T) or placebo (P)a
| Mouse type and treatment | HR (bpm) | LVSP (mm Hg) | LVEDP (mm Hg) | +dP/dt | −dP/dt |
|---|---|---|---|---|---|
| β-Cateninfl/fl/Cre, P (n = 8) | 585 ± 11 | 142 ± 8 | 10.7 ± 2.0 | 8,494 ± 305 | 8,256 ± 364 |
| β-Cateninfl/fl/Cre, T (n = 7) | 550 ± 21 | 143 ± 5 | 12.8 ± 1.6 | 8,389 ± 398 | 8,691 ± 453 |
| β-Cateninfl/fl/WT, T (n = 8) | 568 ± 13 | 146 ± 5 | 12.8 ± 2.0 | 7,959 ± 355 | 8,326 ± 341 |
a
HR, heart rate; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; +dP/dt, first derivative of the rate of rise of LV pressure in systole; −dP/dt, first derivative of the rate of fall of LV pressure in diastole; bpm, beats per minute. The P value was not significant for all parameters.